Phase II/III, Randomized, Clinical Trial of the Effects of Nutropin AQ® on Growth and Bone Metabolism in Children With MPS I, II, and VI and Short Stature
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Change in Growth Velocity From Baseline to End of Study Year 1.
研究概览
简要总结
The purpose of this study is to determine whether growth hormone is a safe and effective treatment for short stature in children with Mucopolysaccharidosis type I, II, and VI.
详细描述
Although children with MPS I, II, and VI who are treated with Hematopoietic Cell Transplantation (HCT) and/or enzyme replacement therapy (ERT) are living into adulthood with good cognitive development, their quality of life is significantly impacted by their skeletal abnormalities (i.e., kyphosis, scoliosis, and genu valgum), contractures, and severe short stature. Here at the University of Minnesota we have seen some promising clinical outcomes in children with MPS IH whom we have treated with human growth hormone (hGH). There are currently no reports in the literature of the impact of treating children with MPS and short stature, with hGH on their growth velocity or characteristic skeletal abnormalities. This study will advance the care of these children by providing data in this yet unexplored area of pediatric medicine with the goal of improving the quality of life for these children by improving height, mobility, and neuropsychological functioning.
This is a Phase II/III randomized, single-center, 12 month clinical trial of growth hormone in male and female participants with MPS I, II, or VI, followed by 12 months open label. Participants with height ≤ -2 SDS for age and gender will be randomized for the first 12 months 1:1 to treatment or no treatment. At the conclusion of the 12 months, all subjects will be offered an additional 12 months of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 5 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A parent or legally authorized representative must provide written informed consent and comply with study assessments for the full duration of the study.
- •Chronologic age ≥ 5 years and bone age ≤12 years
- •Diagnosis of MPS I, II, or VI
- •Height ≤ -2 SDS for age and gender
- •Ability to travel to study center for evaluations.
- •Ability of the participant to cooperate with study procedures, to notify a guardian of symptoms, and provide assent for participation in the study.
排除标准
- •History of treatment with hGH
- •Untreated pituitary deficiency
- •Pregnancy (positive urine pregnancy test) prior to enrollment in the study
- •Participation in another simultaneous medical intervention trial
- •Patients with closed epiphysis
- •Active neoplasm
- •Orthopedic procedure of the femur within the last 6 months.
- •Known or suspected allergy to trial product or related products.
- •Structural lesion on brain MRI resulting in brain compression
- •Any other social or medical condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.
- •Obstructive sleep apnea without BiPAP or tonsillectomy/adenoidectomy treatment.
- •CNS shunt.
- •Abnormal cardiac function based on echocardiogram within 6 months prior to enrollment :
- •Ejection fraction less than 50%
- •Left ventricular chamber size greater than or less than 2 standard deviations of normal for body surface area
- •Left ventricular wall thickness greater than or less than 2 standard deviations of normal for body surface area
- •More than mild to moderate aortic insufficiency with abdominal aortic run-off
- •More than mild to moderate mitral insufficiency with pulmonary hypertension
- •Abnormal pulmonary function based on pulmonary function tests within 6 months prior to enrollment:
- •abnormal FVC < 80% of predicted for age, gender, and height
- •abnormal FEV1 < 80% predicted for age, gender, and height
- •abnormal FEV1/FVC
- •abnormal oxygen saturation
研究组 & 干预措施
Growth hormone treatmen
Growth hormone treatment arm. Somatropin (DNA origin)
干预措施: Somatropin (DNA origin) (Drug)
结局指标
主要结局
Change in Growth Velocity From Baseline to End of Study Year 1.
时间窗: 12 months
次要结局
- Safety: Number Drug Related SAEs(1 months)